Background {#Sec1}
==========

Age-related Macular Degeneration (AMD) is a progressive disease that preferentially affects the macular region of the retina \[[@CR1]\]. It has a total population of about 170 million individuals who are affected with AMD globally, thus being the third leading cause of vision loss in the world \[[@CR2], [@CR3]\]. In the United States, the prevalence of AMD reaches 11 million, similar to that of all invasive cancers combined, leading to an annual \$4.6 billion direct healthcare cost \[[@CR4]\]. However, different regions showed different patterns of AMD burden. The Beijing Eye Study \[[@CR5], [@CR6]\] showed that visual loss owing to AMD was comparatively uncommon in China, and obviously less than in the Western. On the contrary, some other studies \[[@CR7], [@CR8]\] presented that the prevalence of AMD in Asian populations was comparable with white populations. In the Singapore Chinese Eye Study \[[@CR9]\], it was reported that early AMD was more common in Chinese and Indians than in Malays, further underlining the widespread difference in regions. To better explain this difference, we use disability-adjusted life years (DALYs) as a main measurement to make comparisons across latitude, socioeconomic status, education years, public health expenditure and so on. DALYs are the sum of years lived with disability (YLDs) and years of life lost (YLLs) owing to premature death. As for AMD, DALYs equal YLDs in general. Therefore, this study was to explore the underlying mechanisms on the difference of AMD burden among different regions, using the DALY data available from the Global Burden of Disease (GBD) 2017 study \[[@CR10]\].

Methods {#Sec2}
=======

Overview {#Sec3}
--------

The GBD study aims to explore health loss due to diseases, injuries, and risk factors by age, sex, and geography. Additional detail on GBD metrics and definitions can be found elsewhere \[[@CR11]\]. Detailed methods for estimating DALYs have been mentioned in related publications \[[@CR12], [@CR13]\]. Importantly, all countries share the same disability weights \[[@CR14]\]. There were no ethical issues involved in this study as the data shown here were all extracted from the websites online.

Data extraction {#Sec4}
---------------

Global burden of AMD was estimated in terms of DALYs in the GBD 2017 study including 189 countries. The following data regarding AMD burden were collected \[[@CR10]\]: (1) global DALYs, DALYs per 100,000 population and age-standardized DALYs per 100,000 population during 1990 to 2015, (2) national age-standardized DALYs per 100,000 population in 2015 and 2017.

Google Earth was used to identify the latitude of each country, with \< 30° defined as low latitude, \> 60°as high latitude, and as medium latitude when in between.

The Human Development Index (HDI) is a composite measurement of health, education and income of a country, ranging from 0 to 1, with a higher value representing a corresponding higher level of socioeconomic status. Based on the Human Development Report \[[@CR15]\], the data were extracted from the United Nations Development Programme (UNDP) database as follows: (1) HDI data in 2017, (2) national mean education years in 2017 and (3) national public health expenditure in 2015. According to the UNDP categorization, countries were divided into 4 groups in 2017: very high, high, medium and low.

Statistical analysis {#Sec5}
--------------------

The differences of age-standardized DALY rates among three latitude-based country groups as well as four HDI-based groups were compared using Kruskal-Wallis test, followed by Dunn's multiple comparisons test \[[@CR16], [@CR17]\]. Linear regression analysis was performed to investigate the effect of national HDI, national mean education years and national public health expenditure on age-standardized DALY rates. All statistical analyses were performed using SPSS 24 (IBM Corporation, Chicago, Illinois, USA). *P* values of less than 0.05 were considered statistically significant.

Results {#Sec6}
=======

AMD burden by year {#Sec7}
------------------

Global DALY numbers caused by AMD rose by 108.2%, from 2.5 million in 1990 to 5.3 million in 2017 (Fig. [1](#Fig1){ref-type="fig"}a). Consistently, DALY rates increased by 46.9% from 4.73 to 6.95 after controlling population size between 1990 and 2017 (Fig. [1](#Fig1){ref-type="fig"}b). On this basis, we further removed the impact of a growing world population and composition changes during the same period, showing that the AMD burden in terms of age-standardized DALY rates increased slightly by 4.2% from 6.85 to 7.14 during 1990 to 1995, then dropped by 3.4% to 6.9 in 2000, followed by a relatively constant period until 2011, and decreased year by year during 2011 to 2017 (Fig. [1](#Fig1){ref-type="fig"}c). Fig. 1Changes in global burden of Age-related Macular Degeneration (AMD) in terms of disability-adjusted life years (DALY) numbers (left), DALY rates (middle), and age-standardized DALY rates (right) between 1990 and 2017. Lines represent 95% uncertainty intervals

AMD burden by region in 2017 {#Sec8}
----------------------------

There are 189 countries in total included in the GBD 2017 study, covering 47 African countries, 35 American countries, 10 South-East Asian countries, 50 European countries, 21 Eastern Mediterranean countries and 24 Western Pacific countries. Results of analysis using Kruskal-Wallis test showed a significant difference of age-standardized DALYs per 100,000 population among six WHO regions (*P* \< 0.0001, Fig. [2](#Fig2){ref-type="fig"}). Further performing Dunn's multiple comparison test showed that the AMD burdens of African and Eastern Mediterranean regions were significantly higher than American, South-East Asian, European and Western Pacific regions (*P* = 0.0004, *P* = 0.0421, *P* = 0.0002, *P* \< 0.0001, respectively in African comparisons; P \< 0.0001, *P* = 0.0003, P \< 0.0001, P \< 0.0001, respectively in Eastern Mediterranean comparisons). Fig. 2Global burden of Age-related Macular Degeneration (AMD) in terms of age-standardized disability-adjusted life years (DALY) rates by World Health Organization (WHO) region in 2017. Lines represent 95% uncertainty intervals

AMD burden by latitude in 2017 {#Sec9}
------------------------------

Latitude data were available for 189 countries by Google Earth, including 4 high-latitude countries, 67 medium-latitude countries and 118 low-latitude countries. Kruskal-Wallis test indicated that age-standardized DALY rates shared no significant difference among countries of different latitude groups (*P* = 0.0896, Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Global burden of Age-related Macular Degeneration (AMD) in terms of age-standardized disability-adjusted life years (DALY) rates by national latitude in 2017. AMD burden differed among countries with different latitude levels. Lines represent 95% uncertainty intervals

AMD burden by socioeconomic development in 2017 {#Sec10}
-----------------------------------------------

HDI data in 2017 were available for 189 countries, including 59 very high-HDI, 53 high-HDI, 39 medium-HDI and 38 low-HDI countries. Kruskal-Wallis tests indicated that age-standardized DALY rates differed significantly among countries with different socioeconomic development levels (*P* \< 0.0001). Multiple comparisons using Dunn's test revealed that very high-, high- and medium- HDI countries had significantly higher age-standardized DALY rates than low-HDI ones (Fig. [4](#Fig4){ref-type="fig"}a). Linear regression analysis suggested that HDI had a significant effect on age-standardized DALY rates (adjusted R^2^ = 0.024; *P* = 0.019). As can be seen in Fig. [4](#Fig4){ref-type="fig"}b, age-standardized DALY rates were inversely associated with HDI (standardized β = − 0.173, P = 0.019). Fig. 4Global burden of Age-related Macular Degeneration (AMD) in terms of age-standardized disability-adjusted life years (DALY) rates by national socioeconomic development in 2017. (Left) AMD burden differed among countries with different socioeconomic development levels. Lines represent the median burden. \**P* \< 0.05, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. (Right) AMD burden was inversely associated with socioeconomic development level. The line represents a linear fit

AMD burden by education in 2017 {#Sec11}
-------------------------------

Linear regression analysis indicated that mean education years had a significant effect on age-standardized DALY rates (adjusted R^2^ = 0.071; *P* \< 0.001). As can be seen in Fig. [5](#Fig5){ref-type="fig"}, age-standardized DALY rates were inversely associated with mean education years (standardized β = − 0.276, P \< 0.001). Fig. 5Global burden of Age-related Mcular Degeneration (AMD) in terms of age-standardized disability-adjusted life years (DALY) rates by mean education years in 2017

AMD burden by public health expenditure in 2015 {#Sec12}
-----------------------------------------------

Results showed that public health expenditure had no significant effect on age-standardized DALY rates (*P* = 0.331) by linear regression analysis (Fig. [6](#Fig6){ref-type="fig"}). Fig. 6Global burden of Age-related Macular Degeneration (AMD) in terms of age-standardized disability-adjusted life years (DALY) rates by public health expenditure in 2015

Construction of a multivariate linear regression model {#Sec13}
------------------------------------------------------

According to the results above, we included HDI and mean education years as the independent factors to construct a multivariate linear regression model of age standardized DALYs. A significant correlation was found (*P* \< 0.001) and this model can explain 11.3% of the variance in regional difference of AMD burden.

Discussion {#Sec14}
==========

This study aimed to explain why different regions held different AMD burden, and made efforts on the roles that latitude, socioeconomic status, education and public health expenditure played in the regional disparity. After excluding the influence of population size and composition, we found that AMD burden decreased recently in terms of age-standardized DALY rates, while the absolute DALY numbers and rates both had an evident increase. This result can be explained as follows: with the development of medical technology and related devices, the diagnostic rates, cure rates and life expectancy increase notably in recent years. On the other hand, the introduction of anti-vascular endothelial growth factor (VEGF) therapy for neovascular AMD has offered remarkable clinical benefits \[[@CR18]\], leading to atrophy of neovascularization. Ranibizumab, bevacizumab and aflibercept are the most common drugs used in the therapy of neovascular AMD \[[@CR19]\], and the off-label use of bevacizumab is in consideration of reducing the cost \[[@CR20]--[@CR22]\], although some studies also indicated a high frequency of serious adverse events in the patients receiving bevacizumab therapy \[[@CR23]--[@CR25]\]. These all contributed to the recent downtrend of AMD burden.

The patterns of AMD burden in different regions have been controversial so far. Some population studies (the Age-Related Eye Disease Study \[[@CR26]\], the Beijing Eye Study \[[@CR5], [@CR6]\], the Los Angeles Latino Eye Study \[[@CR27]\], and the study \[[@CR2]\] by Wong et al.) showed that the prevalence of AMD was higher in the white; still, the statistic results of other studies (the National Health and Nutrition Examination Survey III \[[@CR28]\], the multi-ethnic study of atherosclerosis \[[@CR29]\], a multiethnic Asian cohort study \[[@CR7]\] and the Nagahama study \[[@CR8]\]) showed that there were no significant difference among different regions. In our study, results showed that the African and Eastern Mediterranean regions held higher AMD burden than the American, South-East Asian and Western Pacific regions, and the latter three regions shared no significant difference of AMD burden (Fig. [2](#Fig2){ref-type="fig"}). Apart from the parts of genetic factors played therein, we cannot deny the roles of environmental factors in the region difference of AMD burden. Therefore, this study was in an attempt to explain this difference from several region-related aspects, such as latitude, socioeconomic status, education level, public health expenditure and so on.

The relationship between latitude and AMD burden has rarely been studied so far. In our study, it was shown that AMD burden was comparable among different latitude groups. In past publications, sun insolation was expected to be related with AMD burden. It was said that high sun insolation destroyed retina pigment epithelium (RPE) cells, which is a critical part in the development of AMD \[[@CR30]\]. Besides, the function of vitamin D in the pathogenesis of AMD was also a concern as the immunomodulatory and antiangiogenic properties of vitamin D were assumed to protect persons from AMD \[[@CR31]\]. The result in our study did not deny the role of latitude as well as sun insolation in AMD burden, but should be further verified after excluding confounding factors.

It is no wonder that high socioeconomic level contributes to the decrease of disease burden, as more developed countries are expected to be equipped with better healthcare systems and provide more persons with regular physical examinations to realize early detection, diagnosis and treatment of diseases. In our study, AMD burden differed significantly among regions of different socioeconomic status, and a negative relationship existed between these two parameters (Fig. [4](#Fig4){ref-type="fig"}). As for WHO region system, HDI differed significantly in different WHO regions (*P* \< 0.0001); the countries of the European region, whose AMD burden was low, had the highest HDI; while African countries with high AMD burden held the lowest one, with the rest four regions sharing no significant difference of HDI (Fig. [7](#Fig7){ref-type="fig"}). Fig. 7Human Development Index by World Health Organization (WHO) region in 2017. Lines represent 95% uncertainty intervals

To deeply probe the underlying factors that impacted the region disparity of AMD burden, we further analyzed the relationship between education level/Public Health Expenditure and AMD burden. It was not surprising to find that the AMD burden was lighter where mean education years were longer. Low education is related to lack of awareness about health care, thus leading to low visiting rates and low compliance to treatment. Previous studies also showed that individuals with low education were less likely to visit an eye care professional \[[@CR32]--[@CR34]\]. Further interpreting results based on WHO region system, mean education years differed in different WHO regions. Also, the European region provided the most education years, undoubtedly owning a comparatively low AMD burden. By contrast, the African region with a comparatively high AMD burden provided the fewest education years (Fig. [8](#Fig8){ref-type="fig"}). The role of public health expenditure in AMD burden was not obvious in this study; however, the lack of data about the discrete public health expenditure on AMD made this result not so convincing, as different governments treated AMD in their own ways according to prevalence and case fatality rate of AMD in the certain country. Fig. 8Mean education years of by World Health Organization (WHO) region in 2017. Lines represent 95% uncertainty intervals

DALYs have its own unique computing method different from the universal epidemiological indicators (prevalence, incidence, et al.) \[[@CR10]\], which is the total of years lived with disability (YLDs) and years of life lost (YLLs) owing to premature death. So the application of DALYs can provide a novel insight into the global burden of diseases. Owen et al. \[[@CR35]\] showed in 2012 that the estimated prevalence of late AMD was 2.4% (95% credible interval (CrI) 1.7 to 3.3%) in UK 2007--2009 population, while ISAO NAKATA et al. \[[@CR8]\] represented in the article that the overall prevalence in 2008--2010 Japanese population of early and late AMD were 22.8% (95% confidence interval (CI) 21.7--24.0%) and 0.58% (95% CI 0.36--0.80%) respectively. This result is consistent with past publication \[[@CR2]\] that the white own higher prevalence though contradictory to what we found in this study. It is a reasonable speculation that DALYs are highly influenced by socioeconomic status, education level and public health expenditure as listed above, and the white who own advanced socioeconomic development, excellent education environment and high public health expenditure undoubtedly have low DALYs.

This study was subjected to the limitations which had been noted in the GBD 2017 study, such as data sources and statistical assumption \[[@CR13], [@CR14]\]. Besides, the division of different latitude groups was based on which latitude range the majority of areas was located on, and the existence of countries covering more than one latitude range might influence the accuracy of results.

Conclusion {#Sec15}
==========

This study is the first to explain the regional differences of AMD burden from latitude, socioeconomic status, education and public health expenditure. The results showed a decreased level of global burden of AMD recently with significant disparity across different WHO regions; the African region with the lowest HDI and the fewest education years had a considerably high AMD burden; and the European region in the contrary with the highest HDI and the most education years owned a fairly low AMD burden. This phenomenon highlights the need to reduce the AMD burden especially in the developing countries, and pay more attention to education with related policy improved and publicity strengthened. More discrete data are needed to support the roles of latitude and public health expenditure in regional differences of AMD burden.
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